You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,865,730


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,865,730 protect, and when does it expire?

Patent 8,865,730 protects ZYDELIG and is included in one NDA.

This patent has thirty-five patent family members in thirty countries.

Summary for Patent: 8,865,730
Title:Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e
Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e, compositions thereof, methods for their preparation, and methods for their use are disclosed.
Inventor(s): Carra; Ernest (Foster City, CA), Gerber; Michael (Oakland, CA), Shi; Bing (Redwood city, CA), Sujino; Keiko (Edmonton, CA), Tran; Duong (Edmonton, CA), Wang; Fang (Foster City, CA), Evarts; Jerry B. (Redmond, WA)
Assignee: Gilead Calistoga LLC (Foster City, CA)
Application Number:13/786,222
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition; Dosage form; Use;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope and Claims of United States Patent 8,865,730

Introduction

United States Patent 8,865,730, titled "Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one," is a patent that covers specific polymorphic forms of a quinazolinone compound. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background of the Invention

The patent involves cell signaling via 3′-phosphorylated phosphoinositides, which are implicated in various cellular processes, including malignant transformation and growth factor signaling. The compound in question is a quinazolinone derivative, which is a class of compounds known for their therapeutic potential, particularly in cancer treatment[4].

Scope of the Invention

The scope of the invention is focused on the polymorphic forms of the compound (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one. Polymorphism in pharmaceuticals is crucial as it can affect the physical and chemical properties of the drug, such as solubility, stability, and bioavailability.

Polymorphic Forms

The patent describes two main polymorphic forms: Form I and Form II.

Polymorphic Form I

  • This form is characterized by an X-ray powder diffraction pattern with peaks at specific degrees (e.g., 14.3°, 17.2°, 17.7°, 20.9°, 23.9°, and 24.9° 2θ).
  • It has a melting temperature range of about 254°C to 256°C.
  • The method of preparation involves combining the compound with a solvent, heating to form a solution, and then cooling to form the polymorphic Form I[4].

Polymorphic Form II

  • This form is obtained by grinding polymorphic Form I and then stirring it in a solvent.
  • It is characterized by an X-ray powder diffraction pattern with peaks at different degrees (e.g., 18.6°, 24.3°, and 14.0° 2θ).
  • The grinding process can be performed using various methods, and the solvent used can include organic solvents like acetone[4].

Claims of the Patent

The claims of the patent are critical as they define the legal boundaries of the invention.

Independent Claims

  • The patent includes claims that describe the polymorphic forms (Form I and Form II) of the compound, their X-ray powder diffraction patterns, and the methods for preparing these forms.
  • For example, Claim 1 might describe the polymorphic Form I with its specific X-ray powder diffraction peaks and melting temperature range[4].

Dependent Claims

  • Dependent claims further specify the methods of preparation, including the solvents used and the conditions for heating and cooling.
  • These claims also cover various embodiments of the grinding process for obtaining polymorphic Form II[4].

Patent Landscape

Understanding the patent landscape is essential for assessing the competitive environment and potential opportunities or threats.

Prior Art

  • The patent cites prior art related to quinazolinone compounds and their polymorphic forms. This includes other patents and publications that describe similar compounds and their properties[4].

Global Dossier

  • Using tools like the Global Dossier, one can access the file histories of related applications from participating IP Offices. This helps in understanding the global patent family and any office actions or citations related to this patent[1].

Common Citation Document (CCD)

  • The CCD application consolidates prior art cited by all participating offices for the family members of a patent application. This can provide a comprehensive view of the prior art landscape relevant to this patent[1].

Patent Analytics

To fully understand the value and coverage of this patent, patent analytics can be employed.

Claim Coverage Matrix

  • A Claim Coverage Matrix can show which patents and claims are actively protecting the intellectual property and where gaps or opportunities exist. This is particularly useful for companies with large patent portfolios[3].

Scope Concepts

  • Categorizing patents by scope concepts helps in filtering, searching, and analyzing large numbers of patent claims. This method can highlight the value of the patent claims in relation to the company's current and future products[3].

Legal Considerations

The legal validity and defenses of the patent are crucial.

Presumption of Validity

  • Under 35 USC 282, each claim of a patent is presumed valid. This means that any challenge to the patent must overcome this presumption[5].

Defenses

  • Defenses against patent infringement claims can include invalidity based on prior art, obviousness, or other grounds. Understanding these defenses is vital for both the patent holder and potential infringers[5].

Key Takeaways

  • Polymorphic Forms: The patent covers two specific polymorphic forms (Form I and Form II) of the quinazolinone compound.
  • Claims: The claims define the polymorphic forms, their preparation methods, and the X-ray powder diffraction patterns.
  • Patent Landscape: Understanding the global patent family and prior art is essential for navigating the competitive environment.
  • Patent Analytics: Tools like Claim Coverage Matrix and scope concepts help in analyzing the patent portfolio and identifying gaps or opportunities.
  • Legal Considerations: The patent is presumed valid, and any challenges must overcome this presumption.

FAQs

What is the significance of polymorphic forms in pharmaceuticals?

Polymorphic forms can significantly affect the physical and chemical properties of a drug, such as solubility, stability, and bioavailability, which are critical for its efficacy and safety.

How are the polymorphic forms of the compound prepared?

Polymorphic Form I is prepared by combining the compound with a solvent, heating to form a solution, and then cooling. Polymorphic Form II is obtained by grinding Form I and stirring it in a solvent.

What tools can be used to analyze the patent landscape?

Tools such as the Global Dossier and Common Citation Document (CCD) can be used to access file histories and prior art citations related to the patent.

Why is patent analytics important for this patent?

Patent analytics helps in understanding which patents and claims are actively protecting the intellectual property and where gaps or opportunities exist, which is crucial for strategic decision-making.

What is the legal presumption regarding the validity of this patent?

Each claim of the patent is presumed valid under 35 USC 282, and any challenge must overcome this presumption.

Sources

  1. USPTO: Search for patents - USPTO.
  2. ACUS: U.S. Patent Small Claims Court.
  3. SLWIP: Patent Analytics | Intellectual Property Law.
  4. Google Patents: US8865730B2 - Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one.
  5. US Code: 35 USC 282: Presumption of validity; defenses.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,865,730

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No 8,865,730 ⤷  Subscribe Y Y FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL ⤷  Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes 8,865,730 ⤷  Subscribe Y Y FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.